nodes	percent_of_prediction	percent_of_DWPC	metapath
Droperidol—Pimozide—Ezetimibe—atherosclerosis	0.48	0.521	CrCrCtD
Droperidol—Fluspirilene—Ezetimibe—atherosclerosis	0.441	0.479	CrCrCtD
Droperidol—HTR2A—arteriole—atherosclerosis	0.00505	0.274	CbGeAlD
Droperidol—HTR2A—vein—atherosclerosis	0.00301	0.163	CbGeAlD
Droperidol—HTR2A—hindlimb—atherosclerosis	0.002	0.108	CbGeAlD
Droperidol—HTR2A—appendage—atherosclerosis	0.00172	0.093	CbGeAlD
Droperidol—Fluspirilene—HRH1—atherosclerosis	0.00142	0.356	CrCbGaD
Droperidol—Laryngospasm—Niacin—atherosclerosis	0.0014	0.05	CcSEcCtD
Droperidol—Gynaecomastia—Rosuvastatin—atherosclerosis	0.00129	0.0459	CcSEcCtD
Droperidol—HTR2A—artery—atherosclerosis	0.00123	0.0664	CbGeAlD
Droperidol—Gynaecomastia—Lovastatin—atherosclerosis	0.00109	0.0389	CcSEcCtD
Droperidol—Pimozide—HRH1—atherosclerosis	0.00106	0.266	CrCbGaD
Droperidol—HTR2A—endothelium—atherosclerosis	0.00104	0.0561	CbGeAlD
Droperidol—Gynaecomastia—Simvastatin—atherosclerosis	0.00102	0.0364	CcSEcCtD
Droperidol—Haloperidol—HRH1—atherosclerosis	0.000967	0.243	CrCbGaD
Droperidol—HTR2A—blood vessel—atherosclerosis	0.000956	0.0518	CbGeAlD
Droperidol—Gynaecomastia—Pravastatin—atherosclerosis	0.000922	0.0329	CcSEcCtD
Droperidol—Depression—Rosuvastatin—atherosclerosis	0.000802	0.0286	CcSEcCtD
Droperidol—ADRA1A—cardiovascular system—atherosclerosis	0.00066	0.0357	CbGeAlD
Droperidol—KCNH2—cardiovascular system—atherosclerosis	0.000637	0.0345	CbGeAlD
Droperidol—Depression—Simvastatin—atherosclerosis	0.000635	0.0227	CcSEcCtD
Droperidol—ADRA1A—adipose tissue—atherosclerosis	0.000582	0.0315	CbGeAlD
Droperidol—Depression—Pravastatin—atherosclerosis	0.000574	0.0205	CcSEcCtD
Droperidol—Angioedema—Rosuvastatin—atherosclerosis	0.000574	0.0205	CcSEcCtD
Droperidol—Chills—Lovastatin—atherosclerosis	0.000549	0.0196	CcSEcCtD
Droperidol—Fenbufen—PTGS2—atherosclerosis	0.000541	0.136	CrCbGaD
Droperidol—Chills—Simvastatin—atherosclerosis	0.000513	0.0183	CcSEcCtD
Droperidol—HTR2A—connective tissue—atherosclerosis	0.00049	0.0265	CbGeAlD
Droperidol—Angioedema—Lovastatin—atherosclerosis	0.000487	0.0174	CcSEcCtD
Droperidol—Angioedema—Ezetimibe—atherosclerosis	0.000477	0.017	CcSEcCtD
Droperidol—Chills—Niacin—atherosclerosis	0.000471	0.0168	CcSEcCtD
Droperidol—Chills—Pravastatin—atherosclerosis	0.000464	0.0166	CcSEcCtD
Droperidol—Palpitations—Ezetimibe—atherosclerosis	0.000461	0.0165	CcSEcCtD
Droperidol—Angioedema—Simvastatin—atherosclerosis	0.000455	0.0162	CcSEcCtD
Droperidol—Anxiety—Lovastatin—atherosclerosis	0.000452	0.0161	CcSEcCtD
Droperidol—Hypertension—Ezetimibe—atherosclerosis	0.000451	0.0161	CcSEcCtD
Droperidol—Anaphylactic shock—Lovastatin—atherosclerosis	0.000435	0.0155	CcSEcCtD
Droperidol—HTR2A—cardiovascular system—atherosclerosis	0.000427	0.0231	CbGeAlD
Droperidol—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000426	0.0152	CcSEcCtD
Droperidol—Anxiety—Simvastatin—atherosclerosis	0.000423	0.0151	CcSEcCtD
Droperidol—Angioedema—Niacin—atherosclerosis	0.000418	0.0149	CcSEcCtD
Droperidol—Angioedema—Pravastatin—atherosclerosis	0.000411	0.0147	CcSEcCtD
Droperidol—Syncope—Niacin—atherosclerosis	0.00041	0.0146	CcSEcCtD
Droperidol—ADRA1A—liver—atherosclerosis	0.000408	0.0221	CbGeAlD
Droperidol—Anaphylactic shock—Simvastatin—atherosclerosis	0.000406	0.0145	CcSEcCtD
Droperidol—Palpitations—Niacin—atherosclerosis	0.000404	0.0144	CcSEcCtD
Droperidol—Loss of consciousness—Niacin—atherosclerosis	0.000402	0.0143	CcSEcCtD
Droperidol—Hypertension—Pravastatin—atherosclerosis	0.000389	0.0139	CcSEcCtD
Droperidol—Anxiety—Pravastatin—atherosclerosis	0.000382	0.0136	CcSEcCtD
Droperidol—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000378	0.0135	CcSEcCtD
Droperidol—Anaphylactic shock—Niacin—atherosclerosis	0.000373	0.0133	CcSEcCtD
Droperidol—Anaphylactic shock—Pravastatin—atherosclerosis	0.000367	0.0131	CcSEcCtD
Droperidol—Shock—Niacin—atherosclerosis	0.000367	0.0131	CcSEcCtD
Droperidol—Tachycardia—Niacin—atherosclerosis	0.000364	0.013	CcSEcCtD
Droperidol—Hypotension—Niacin—atherosclerosis	0.000349	0.0124	CcSEcCtD
Droperidol—Body temperature increased—Lovastatin—atherosclerosis	0.000344	0.0123	CcSEcCtD
Droperidol—Dizziness—Rosuvastatin—atherosclerosis	0.000339	0.0121	CcSEcCtD
Droperidol—Body temperature increased—Ezetimibe—atherosclerosis	0.000337	0.012	CcSEcCtD
Droperidol—Somnolence—Niacin—atherosclerosis	0.000332	0.0118	CcSEcCtD
Droperidol—Rash—Rosuvastatin—atherosclerosis	0.000323	0.0115	CcSEcCtD
Droperidol—Dermatitis—Rosuvastatin—atherosclerosis	0.000323	0.0115	CcSEcCtD
Droperidol—Body temperature increased—Simvastatin—atherosclerosis	0.000321	0.0115	CcSEcCtD
Droperidol—Hypersensitivity—Lovastatin—atherosclerosis	0.00032	0.0114	CcSEcCtD
Droperidol—Hypersensitivity—Ezetimibe—atherosclerosis	0.000314	0.0112	CcSEcCtD
Droperidol—Hypersensitivity—Simvastatin—atherosclerosis	0.000299	0.0107	CcSEcCtD
Droperidol—Body temperature increased—Niacin—atherosclerosis	0.000295	0.0105	CcSEcCtD
Droperidol—Body temperature increased—Pravastatin—atherosclerosis	0.00029	0.0104	CcSEcCtD
Droperidol—Dizziness—Lovastatin—atherosclerosis	0.000287	0.0103	CcSEcCtD
Droperidol—Dizziness—Ezetimibe—atherosclerosis	0.000282	0.0101	CcSEcCtD
Droperidol—Hypersensitivity—Niacin—atherosclerosis	0.000275	0.00981	CcSEcCtD
Droperidol—Rash—Lovastatin—atherosclerosis	0.000274	0.00977	CcSEcCtD
Droperidol—Dermatitis—Lovastatin—atherosclerosis	0.000274	0.00976	CcSEcCtD
Droperidol—Hypersensitivity—Pravastatin—atherosclerosis	0.000271	0.00966	CcSEcCtD
Droperidol—Dizziness—Simvastatin—atherosclerosis	0.000269	0.00959	CcSEcCtD
Droperidol—Rash—Ezetimibe—atherosclerosis	0.000269	0.00959	CcSEcCtD
Droperidol—Dermatitis—Ezetimibe—atherosclerosis	0.000268	0.00958	CcSEcCtD
Droperidol—HTR2A—liver—atherosclerosis	0.000264	0.0143	CbGeAlD
Droperidol—Rash—Simvastatin—atherosclerosis	0.000256	0.00914	CcSEcCtD
Droperidol—Dermatitis—Simvastatin—atherosclerosis	0.000256	0.00913	CcSEcCtD
Droperidol—Dizziness—Niacin—atherosclerosis	0.000247	0.0088	CcSEcCtD
Droperidol—Dizziness—Pravastatin—atherosclerosis	0.000243	0.00867	CcSEcCtD
Droperidol—Rash—Niacin—atherosclerosis	0.000235	0.00839	CcSEcCtD
Droperidol—Dermatitis—Niacin—atherosclerosis	0.000235	0.00839	CcSEcCtD
Droperidol—Rash—Pravastatin—atherosclerosis	0.000232	0.00827	CcSEcCtD
Droperidol—Dermatitis—Pravastatin—atherosclerosis	0.000231	0.00826	CcSEcCtD
Droperidol—DRD2—Signaling by GPCR—GHRL—atherosclerosis	2.22e-05	0.000797	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—CCR2—atherosclerosis	2.19e-05	0.000788	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—EDNRA—atherosclerosis	2.19e-05	0.000788	CbGpPWpGaD
Droperidol—HTR2A—SIDS Susceptibility Pathways—IL6—atherosclerosis	2.19e-05	0.000786	CbGpPWpGaD
Droperidol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	2.18e-05	0.000785	CbGpPWpGaD
Droperidol—DRD2—GPCR ligand binding—CCL2—atherosclerosis	2.18e-05	0.000785	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—GHRL—atherosclerosis	2.18e-05	0.000784	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CCL4—atherosclerosis	2.17e-05	0.000782	CbGpPWpGaD
Droperidol—HTR2A—GPCR ligand binding—CCL2—atherosclerosis	2.15e-05	0.000772	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—KNG1—atherosclerosis	2.14e-05	0.00077	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CCL4—atherosclerosis	2.14e-05	0.000769	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—GHRL—atherosclerosis	2.13e-05	0.000768	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—AGTR1—atherosclerosis	2.13e-05	0.000765	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—KNG1—atherosclerosis	2.11e-05	0.000758	CbGpPWpGaD
Droperidol—ADRA1A—GPCR ligand binding—CCL2—atherosclerosis	2.1e-05	0.000756	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—AGTR1—atherosclerosis	2.09e-05	0.000753	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CCL4—atherosclerosis	2.09e-05	0.000753	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—KNG1—atherosclerosis	2.06e-05	0.000742	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—AGTR1—atherosclerosis	2.05e-05	0.000737	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—APOA2—atherosclerosis	2.03e-05	0.00073	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—APOA2—atherosclerosis	2e-05	0.000719	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—APOA2—atherosclerosis	1.96e-05	0.000704	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—KNG1—atherosclerosis	1.94e-05	0.000699	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—UTS2—atherosclerosis	1.94e-05	0.000697	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—AGTR1—atherosclerosis	1.93e-05	0.000695	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—KNG1—atherosclerosis	1.91e-05	0.000688	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—UTS2—atherosclerosis	1.91e-05	0.000686	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—AGTR1—atherosclerosis	1.9e-05	0.000684	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—KNG1—atherosclerosis	1.87e-05	0.000674	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—UTS2—atherosclerosis	1.87e-05	0.000671	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—AGTR1—atherosclerosis	1.86e-05	0.00067	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CX3CR1—atherosclerosis	1.86e-05	0.000668	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CASR—atherosclerosis	1.86e-05	0.000668	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CX3CR1—atherosclerosis	1.83e-05	0.000657	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CASR—atherosclerosis	1.83e-05	0.000657	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CX3CL1—atherosclerosis	1.82e-05	0.000655	CbGpPWpGaD
Droperidol—DRD2—Circadian rythm related genes—IL6—atherosclerosis	1.81e-05	0.000652	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—EDN1—atherosclerosis	1.8e-05	0.000649	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CX3CL1—atherosclerosis	1.79e-05	0.000645	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—CCL5—atherosclerosis	1.79e-05	0.000644	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CASR—atherosclerosis	1.79e-05	0.000644	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CX3CR1—atherosclerosis	1.79e-05	0.000644	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—EDN1—atherosclerosis	1.78e-05	0.000639	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—CCL5—atherosclerosis	1.76e-05	0.000634	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CX3CL1—atherosclerosis	1.76e-05	0.000631	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—EDN1—atherosclerosis	1.74e-05	0.000625	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CNR2—atherosclerosis	1.73e-05	0.000621	CbGpPWpGaD
Droperidol—DRD2—GPCR ligand binding—CXCL8—atherosclerosis	1.73e-05	0.000621	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—CCL5—atherosclerosis	1.73e-05	0.00062	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—MMP3—atherosclerosis	1.72e-05	0.00062	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—PRKCG—atherosclerosis	1.7e-05	0.000612	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CNR2—atherosclerosis	1.7e-05	0.000611	CbGpPWpGaD
Droperidol—HTR2A—GPCR ligand binding—CXCL8—atherosclerosis	1.7e-05	0.000611	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—MMP3—atherosclerosis	1.7e-05	0.00061	CbGpPWpGaD
Droperidol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	1.69e-05	0.000608	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—PRKCG—atherosclerosis	1.68e-05	0.000602	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CNR2—atherosclerosis	1.66e-05	0.000598	CbGpPWpGaD
Droperidol—ADRA1A—GPCR ligand binding—CXCL8—atherosclerosis	1.66e-05	0.000598	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—MMP3—atherosclerosis	1.66e-05	0.000597	CbGpPWpGaD
Droperidol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	1.66e-05	0.000596	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—PRKCG—atherosclerosis	1.64e-05	0.00059	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—EDN1—atherosclerosis	1.64e-05	0.000589	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—CCL5—atherosclerosis	1.63e-05	0.000585	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—EDN1—atherosclerosis	1.61e-05	0.00058	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—CCL5—atherosclerosis	1.6e-05	0.000575	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—EDN1—atherosclerosis	1.58e-05	0.000568	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—CCL5—atherosclerosis	1.57e-05	0.000563	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PRKCG—atherosclerosis	1.55e-05	0.000556	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—VWF—atherosclerosis	1.54e-05	0.000553	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—APOC3—atherosclerosis	1.53e-05	0.00055	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PRKCG—atherosclerosis	1.52e-05	0.000547	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—LDLR—atherosclerosis	1.52e-05	0.000547	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—VWF—atherosclerosis	1.51e-05	0.000545	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—APOC3—atherosclerosis	1.51e-05	0.000541	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—AGT—atherosclerosis	1.5e-05	0.000539	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—LDLR—atherosclerosis	1.5e-05	0.000538	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PRKCG—atherosclerosis	1.49e-05	0.000536	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CCL3—atherosclerosis	1.49e-05	0.000534	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—VWF—atherosclerosis	1.48e-05	0.000533	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—AGT—atherosclerosis	1.47e-05	0.00053	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—APOC3—atherosclerosis	1.47e-05	0.00053	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—LDLR—atherosclerosis	1.46e-05	0.000527	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CCL3—atherosclerosis	1.46e-05	0.000525	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—AGT—atherosclerosis	1.44e-05	0.000519	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CCL3—atherosclerosis	1.43e-05	0.000514	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NCF1—atherosclerosis	1.42e-05	0.000511	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NCF1—atherosclerosis	1.4e-05	0.000503	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—F2—atherosclerosis	1.38e-05	0.000498	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NCF1—atherosclerosis	1.37e-05	0.000493	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—F2—atherosclerosis	1.36e-05	0.00049	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—AGT—atherosclerosis	1.36e-05	0.000489	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CCR2—atherosclerosis	1.34e-05	0.000483	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—EDNRA—atherosclerosis	1.34e-05	0.000483	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—AGT—atherosclerosis	1.34e-05	0.000481	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CYBA—atherosclerosis	1.34e-05	0.000481	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—F2—atherosclerosis	1.33e-05	0.00048	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—PIK3CG—atherosclerosis	1.32e-05	0.000476	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CCR2—atherosclerosis	1.32e-05	0.000475	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—EDNRA—atherosclerosis	1.32e-05	0.000475	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CYBA—atherosclerosis	1.32e-05	0.000473	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—AGT—atherosclerosis	1.31e-05	0.000471	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PLAT—atherosclerosis	1.31e-05	0.000471	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—GHRL—atherosclerosis	1.31e-05	0.000471	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PARP1—atherosclerosis	1.31e-05	0.000471	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—PIK3CG—atherosclerosis	1.3e-05	0.000469	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—EDNRA—atherosclerosis	1.29e-05	0.000465	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CCR2—atherosclerosis	1.29e-05	0.000465	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CYBA—atherosclerosis	1.29e-05	0.000463	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PARP1—atherosclerosis	1.29e-05	0.000463	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—GHRL—atherosclerosis	1.29e-05	0.000463	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PLAT—atherosclerosis	1.29e-05	0.000463	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—PIK3CG—atherosclerosis	1.28e-05	0.000459	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PLAT—atherosclerosis	1.26e-05	0.000453	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—GHRL—atherosclerosis	1.26e-05	0.000453	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PARP1—atherosclerosis	1.26e-05	0.000453	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—F2—atherosclerosis	1.26e-05	0.000452	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—F2—atherosclerosis	1.24e-05	0.000445	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—F2—atherosclerosis	1.21e-05	0.000435	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PIK3CG—atherosclerosis	1.2e-05	0.000433	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PIK3CG—atherosclerosis	1.18e-05	0.000426	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PIK3CG—atherosclerosis	1.16e-05	0.000417	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—KNG1—atherosclerosis	1.15e-05	0.000413	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—AGTR1—atherosclerosis	1.14e-05	0.000411	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—KNG1—atherosclerosis	1.13e-05	0.000406	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—AGTR1—atherosclerosis	1.12e-05	0.000404	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—CCL2—atherosclerosis	1.12e-05	0.000403	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PLG—atherosclerosis	1.11e-05	0.0004	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—KNG1—atherosclerosis	1.11e-05	0.000398	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—CCL2—atherosclerosis	1.1e-05	0.000396	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—AGTR1—atherosclerosis	1.1e-05	0.000396	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PLG—atherosclerosis	1.1e-05	0.000394	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—CCL2—atherosclerosis	1.08e-05	0.000388	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PLG—atherosclerosis	1.07e-05	0.000386	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—SOCS3—atherosclerosis	1.05e-05	0.000379	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—SOCS3—atherosclerosis	1.04e-05	0.000373	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MMP3—atherosclerosis	1.02e-05	0.000366	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—SOCS3—atherosclerosis	1.02e-05	0.000365	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IGF2—atherosclerosis	1.01e-05	0.000364	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MMP3—atherosclerosis	1e-05	0.00036	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IGF2—atherosclerosis	9.97e-06	0.000359	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—APOB—atherosclerosis	9.84e-06	0.000354	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MMP3—atherosclerosis	9.81e-06	0.000353	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IGF2—atherosclerosis	9.76e-06	0.000351	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—CXCL8—atherosclerosis	9.75e-06	0.000351	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—EDN1—atherosclerosis	9.68e-06	0.000348	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—APOB—atherosclerosis	9.68e-06	0.000348	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CCL5—atherosclerosis	9.61e-06	0.000345	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—CXCL8—atherosclerosis	9.6e-06	0.000345	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—EDN1—atherosclerosis	9.53e-06	0.000343	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—APOB—atherosclerosis	9.48e-06	0.000341	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CCL5—atherosclerosis	9.45e-06	0.00034	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—CXCL8—atherosclerosis	9.4e-06	0.000338	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—LPL—atherosclerosis	9.39e-06	0.000338	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—EDN1—atherosclerosis	9.33e-06	0.000335	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CCL5—atherosclerosis	9.26e-06	0.000333	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—LPL—atherosclerosis	9.24e-06	0.000332	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PRKCG—atherosclerosis	9.13e-06	0.000328	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—LPL—atherosclerosis	9.05e-06	0.000325	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PRKCG—atherosclerosis	8.99e-06	0.000323	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—SPP1—atherosclerosis	8.9e-06	0.00032	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—CXCL8—atherosclerosis	8.86e-06	0.000318	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PRKCG—atherosclerosis	8.8e-06	0.000316	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—SPP1—atherosclerosis	8.75e-06	0.000315	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—CXCL8—atherosclerosis	8.72e-06	0.000313	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—SPP1—atherosclerosis	8.57e-06	0.000308	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—CXCL8—atherosclerosis	8.53e-06	0.000307	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PDGFB—atherosclerosis	8.23e-06	0.000296	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PDGFB—atherosclerosis	8.1e-06	0.000291	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—AGT—atherosclerosis	8.04e-06	0.000289	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PDGFB—atherosclerosis	7.93e-06	0.000285	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—AGT—atherosclerosis	7.91e-06	0.000284	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—APOE—atherosclerosis	7.87e-06	0.000283	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—LEP—atherosclerosis	7.87e-06	0.000283	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CAV1—atherosclerosis	7.8e-06	0.000281	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—APOA1—atherosclerosis	7.78e-06	0.00028	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—LEP—atherosclerosis	7.75e-06	0.000279	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—APOE—atherosclerosis	7.75e-06	0.000279	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—AGT—atherosclerosis	7.74e-06	0.000278	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CAV1—atherosclerosis	7.68e-06	0.000276	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—APOA1—atherosclerosis	7.66e-06	0.000275	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—LEP—atherosclerosis	7.59e-06	0.000273	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—APOE—atherosclerosis	7.59e-06	0.000273	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ESR1—atherosclerosis	7.52e-06	0.00027	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CAV1—atherosclerosis	7.52e-06	0.00027	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—APOA1—atherosclerosis	7.5e-06	0.00027	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—F2—atherosclerosis	7.43e-06	0.000267	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ESR1—atherosclerosis	7.4e-06	0.000266	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—F2—atherosclerosis	7.31e-06	0.000263	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ESR1—atherosclerosis	7.24e-06	0.00026	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—F2—atherosclerosis	7.15e-06	0.000257	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	7.11e-06	0.000256	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	6.99e-06	0.000251	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	6.85e-06	0.000246	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	6.81e-06	0.000245	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—INS—atherosclerosis	6.73e-06	0.000242	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	6.7e-06	0.000241	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—INS—atherosclerosis	6.62e-06	0.000238	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CCL2—atherosclerosis	6.62e-06	0.000238	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	6.56e-06	0.000236	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CCL2—atherosclerosis	6.51e-06	0.000234	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IGF1—atherosclerosis	6.51e-06	0.000234	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—INS—atherosclerosis	6.48e-06	0.000233	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IGF1—atherosclerosis	6.4e-06	0.00023	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	6.38e-06	0.000229	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	6.27e-06	0.000225	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	6.18e-06	0.000222	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	6.08e-06	0.000219	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	5.95e-06	0.000214	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NOS3—atherosclerosis	5.9e-06	0.000212	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NOS3—atherosclerosis	5.8e-06	0.000209	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	5.68e-06	0.000204	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CXCL8—atherosclerosis	5.23e-06	0.000188	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	5.15e-06	0.000185	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	5.05e-06	0.000182	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	5.04e-06	0.000181	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—IL6—atherosclerosis	4.98e-06	0.000179	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	4.97e-06	0.000179	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—IL6—atherosclerosis	4.9e-06	0.000176	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	4.87e-06	0.000175	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	4.79e-06	0.000172	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MMP9—atherosclerosis	4.73e-06	0.00017	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NFKB1—atherosclerosis	4.68e-06	0.000168	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MMP9—atherosclerosis	4.66e-06	0.000167	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	4.61e-06	0.000166	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MAPK8—atherosclerosis	4.6e-06	0.000165	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—AKT1—atherosclerosis	4.59e-06	0.000165	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	4.56e-06	0.000164	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	4.53e-06	0.000163	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	4.52e-06	0.000162	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	4.51e-06	0.000162	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	4.43e-06	0.000159	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	4.42e-06	0.000159	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—VEGFA—atherosclerosis	4.25e-06	0.000153	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—STAT3—atherosclerosis	4.21e-06	0.000151	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	4.18e-06	0.00015	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—STAT3—atherosclerosis	4.14e-06	0.000149	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	4.09e-06	0.000147	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	4.05e-06	0.000146	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MAPK3—atherosclerosis	4.02e-06	0.000145	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	3.96e-06	0.000142	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TGFB1—atherosclerosis	3.9e-06	0.00014	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	3.87e-06	0.000139	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	3.84e-06	0.000138	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	3.76e-06	0.000135	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IL6—atherosclerosis	2.94e-06	0.000106	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IL6—atherosclerosis	2.89e-06	0.000104	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IL6—atherosclerosis	2.83e-06	0.000102	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—AKT1—atherosclerosis	2.71e-06	9.75e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—AKT1—atherosclerosis	2.67e-06	9.59e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	2.61e-06	9.39e-05	CbGpPWpGaD
